Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company developing and commercializing medicines that is headquartered in Foster City, California and was founded in 1987. The firm also has locations in La Vernne, California; Oceanside California; San Dimas, California; Miami, Florida; Santa Monica, California; Seattle, Washington; El Segundo, California; and Emeryville, California.

Gilead Sciences specializes in developing and commercializing biopharmaceuticals for HIV/AIDS, liver disease, hematology, oncology, inflammation, respiratory diseases, highly infectious diseases, and viral diseases. Gilead partnered with Kyverna to develop engineering T cell immunotherapies to target autoimmune diseases. The collaboration involves Kyverna’s synthetic Treg platform and synNotch, a synthetic gene expression system from the Kite unit of Gilead.

Gilead Sciences actively participates in community partnerships with COMPASS Initiative, Gilead Lift, Gilead HIV Age Positively, TRANScend, and HepConnect.

With the outbreak of COVID-19, Gilead Sciences began evaluating patients and testing remdesivir in 600 patients with moderate COVID-19 symptoms. They also began treatment of 400 patients with severe symptoms. Their results are expected in May.

Investments

Gilead Sciences has made 12 investments, 3 lead investments, and 4 exits. Notable investments made by Gilead Sciences include: Precision BioSciences, Galapagos, Phenex Pharmaceuticals, Allogene Therapeutics, National AIDS Memorial, Tmunity Therapeutics, AlloVir, Goldfinch Biopharma, Lyndra Therapeutics, and Glympse Bio. Gilead has licensed rights to filgotinib, developed by Galapagos, for rheumatoid arthritis and GLPG1690 for idiopathic pulmonary fibrosis, both in late-stage clinical studies.

Timeline

June 29, 2020

Gilead Sciences Inc announces it has set the price its Covid-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries.

Products

Product

Description

Launch date

Industry

Website

Remdesivir

An antiviral drug candidate also known as GS-5734 developed by Gilead Sciences to treat Ebola virus that shows potential to treat coronavirus 2019-nCoV.

An immunology drug developed by Galapagos and licensed to Gilead Sciences for the treatment of rheumatoid arthritis

Biotechnology

2 Results

Results per page:

Page 1 of 1

People

Name

Role

A Deo

Employee

Aaron Arvey

Employee

Aaron Banner

Employee

Abasi Ene-Obong Ph.D.

Employee

Abrar Farooqui

Employee

Aditya Jhanwar

Employee

Adrienne Eng

Employee

Adrienne Orr

Employee

Ahmed Moussa

Employee

Akshith Mithun

Employee

Alan Stowe

Employee

Alex Derchak

Employee

Alex Iserlis

Employee

Alexandria Tong

Employee

Alexej Ladonnikov

Employee

Alexis C Glasgow

Employee

Alison Dowski

Employee

Alison Lin

Employee

Alistair Barkhouse

Employee

Aliyah Sulaiman

Employee

Ambika Gopalan

Employee

Amer Raza

Employee

Amir Abbas

Employee

Amit Vora

Employee

Amrith Mylvara

Employee

Page 1 of 16

...

Documentaries, videos and podcasts

Title

Date

Link

Companies

Company

CEO

Location

Products/Services

News

Title

Author

Date

Publisher

Description

The Rainmakers: Meet the 20 bankers who closed the biggest deals in a pandemic-stricken year for M&A

Alex Morrell and Reed Alexander

February 11, 2021

Business Insider

The pandemic featured a prolonged M&A drought. But these dealmakers still landed some mammoth transactions as activity roared back.

Gilead Sciences pens early-stage HIV vaccine pact with Gritstone Oncology

Ben Adams

February 1, 2021

FierceBiotech

Initially known as a machine learning biotech focused on cancer, Gritstone Oncology has been broadening its scope to include a very early look at treatments for COVID-19 and, now, another infectious disease.

Global Cell and Gene Therapy Market Report 2020 Featuring Major Players - Gilead Sciences, BMS, Novartis, Amgen, Merck, Organogenesis, Dendreon, Vericel, Bluebird Bio and Fibrocell Science

Research and Markets

January 8, 2021

www.prnewswire.com:443

/PRNewswire/ -- The "Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering....

Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?

Angus Liu

December 30, 2020

FierceBiotech

By using a combination of computational screening tools, scientists at the Chinese Academy of Sciences' Shenzhen Institutes of Advanced Technology showed that Acrotech's Folotyn, a chemotherapy originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19.

Gilead snaps ups German virology biotech MYR, nabbing a European-approved hepatitis D therapy

Ben Adams

December 10, 2020

FierceBiotech

COVID-19 saw its infectious disease credentials reinstated this year, and, now, it's doubling down with a deal to buy out MYR.

Top 16 biotech takeout targets, Bloomberg Intelligence investor survey - Business Insider

Andrew Dunn

December 3, 2020

Business Insider

The drug companies Alexion, Blueprint Medicines, and BioMarin are top M&A targets for 2021, according to a Bloomberg Intelligence survey.

Using Digital Acceleration to Strengthen Your Business - SPONSOR CONTENT FROM WORKDAY

December 1, 2020

Harvard Business Review

Sponsor content from Workday.

HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101

BioSpace

November 30, 2020

BioSpace

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease

Clinical Catch-Up: November 16-20

Mark Terry

November 23, 2020

BioSpace

Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here's a look.

Clinical Catch-Up: November 16-20

Mark Terry

November 23, 2020

BioSpace

COVID-19 Brief: WHO Recommends Against Remdesivir, Roche Ramps Up to Produce Antibodies Treatment and More

Alex Keown

November 20, 2020

BioSpace

The World Health Organization (WHO) recommends against using Gilead Sciences' remdesivir as a treatment for COVID-19.

Hiltzik: Will the U.S. lose its COVID-19 vaccine investment?

Michael Hiltzik

November 16, 2020

Los Angeles Times

The federal government has poured billions into COVID-19 vaccine research, but will Americans reap the profits?

Gilead and Novo Nordisk's Triple-Combo Shows Promise for Untapped NASH Market

Mark Terry

November 16, 2020

BioSpace

Gilead Sciences and Novo Nordisk presented data from a Phase II proof-of-concept clinical trial of semaglutide in combinations with cilofexor and/or firsocostat in non-alcoholic steatohepatitis.

Biopharma Update on the Novel Coronavirus: November 10

BioSpace Editorial Staff

November 10, 2020

BioSpace

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.

ViiV's Cabotegravir Beats Out Gilead's Truvada for Preventing HIV in Women

Mark Terry

November 9, 2020

BioSpace

The pre-specified interim data analysis indicated the drug hit the primary objective of superiority compared to the current standard of care for women.

Q3 Reports: AbbVie, BMS, Allogene, Gilead and AstraZeneca

Mark Terry

November 5, 2020

BioSpace

It's a busy time of year for the biopharma industry, as most companies have begun reporting third-quarter financials.

US regulators allow use of antiviral remdesivir for Covid-19 patients

August 29, 2020

@bsindia

Foster City, California-based Gilead applied to the FDA on Aug. 10 for formal approval of remdesivir, to be sold under the brand name Veklury

Wall Street gains as Gilead data offsets coronavirus fears; Dow leads gains

Reuters

July 10, 2020

@bsindia

Gileads remdesivir significantly improved clinical recovery and reduced the risk of death in Covid-19 patients, additional data from a late-stage study showed.

Remdesivir reduced risk of Covid-19 deaths, but more studies needed: Gilead

Ankur Banerjee| Reuters

July 10, 2020

@bsindia

The company, which had initially released the data from the trial in April, said the finding requires confirmation in clinical trials

Gilead axes $445M Precision Biosciences gene therapy hep B pact

Ben Adams

July 8, 2020

FierceBiotech

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.